These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7783880)

  • 21. Gangliosides in Neurodegenerative Diseases.
    Ledeen R; Chowdhury S
    Adv Neurobiol; 2023; 29():391-418. PubMed ID: 36255682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of GM1 ganglioside in cerebrovascular diseases: a double-blind trial in 40 cases.
    Battistin L; Cesari A; Galligioni F; Marin G; Massarotti M; Paccagnella D; Pellegrini A; Testa G; Tonin P
    Eur Neurol; 1985; 24(5):343-51. PubMed ID: 3902480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic deficiency of GM1 ganglioside in Parkinson's disease tissues and its relation to the disease etiology.
    Ledeen R; Chowdhury S; Lu ZH; Chakraborty M; Wu G
    Glycoconj J; 2022 Feb; 39(1):75-82. PubMed ID: 34973149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo.
    Sommer BR; Cohen BM; Satlin A; Cole JO; Jandorf L; Dorsey F
    J Geriatr Psychiatry Neurol; 1994; 7(4):234-7. PubMed ID: 7826493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between depletion of brain GM1 ganglioside and Parkinson's disease.
    Sonnino S
    FEBS Open Bio; 2023 Sep; 13(9):1548-1557. PubMed ID: 36638010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review.
    Zhang W; Krafft PR; Wang T; Zhang JH; Li L; Tang J
    Cell Transplant; 2019 Jun; 28(6):657-661. PubMed ID: 30666888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gangliosides and parkinsonism.
    Herrero MT; Kastner A; Perez-Otaño I; Hirsch EC; Luquin MR; Javoy-Agid F; Del Río J; Obeso JA; Agid Y
    Neurology; 1993 Oct; 43(10):2132-4. PubMed ID: 8413979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.
    Augustinsson LE; Blennow K; Blomstrand C; Bråne G; Ekman R; Fredman P; Karlsson I; Kihlgren M; Lehmann W; Lekman A; Månsson JE; Ramström I; Wallin A; Wikkelsö C; Gottfries CG; Svennerholm L
    Dement Geriatr Cogn Disord; 1997; 8(1):26-33. PubMed ID: 8997549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
    Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
    Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sensitivity and specificity of anti-GM1 antibody testing.
    Taylor BV; Gross L; Windebank AJ
    Neurology; 1996 Oct; 47(4):951-5. PubMed ID: 8857725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.
    Svennerholm L; Gottfries CG; Blennow K; Fredman P; Karlsson I; Månsson JE; Toffano G; Wallin A
    Acta Neurol Scand; 1990 Jan; 81(1):48-53. PubMed ID: 2330815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel insights on GM1 and Parkinson's disease: A critical review.
    Fazzari M; Di Biase E; Lunghi G; Mauri L; Chiricozzi E; Sonnino S
    Glycoconj J; 2022 Feb; 39(1):27-38. PubMed ID: 35064857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
    Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
    Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
    Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D
    Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants.
    Salazar-Grueso EF; Routbort MJ; Martin J; Dawson G; Roos RP
    Ann Neurol; 1990 May; 27(5):558-63. PubMed ID: 2113790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic treatment with GM1 ganglioside improves survival and function of cryopreserved embryonic midbrain grafted to the 6-hydroxydopamine-lesioned rat striatum.
    Sautter J; Höglinger GU; Oertel WH; Earl CD
    Exp Neurol; 2000 Jul; 164(1):121-9. PubMed ID: 10877922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.